MRSA Carriers: Common but not Uncommon

Methicillin Resistant Staphylococcus aureus (MRSA) is a bacteria that healthcare professionals continue to be concerned due to the potentially serious infections it cause and its resistance to many conventional antibiotics. A MRSA carrier is a person who carries the MRSA on their skin or in their nose but does not exhibit any symptoms. Another name given for this is colonization.

A person may exhibit certain symptoms and signs that indicate they may be MRSA carriers. Specialists in infectious diseases can advise decolonization once the active infection has been treated. By definition, decolonization is a treatment to eradicate Staphylococcus aureus or Methicillin Resistant  Staphylococcus aureus (MRSA) carriage. The most potential benefits of decolonization includes prevention of MRSA transmission and future infection. 

For patients admitted in hospital who are found to be carriers of MRSA, a decolonization treatment plan may be initiated at hospital discharge. Though for community, there are no set guidelines but decolonization may be recommended for those who keep getting MRSA infections despite improving their hygiene practices and/or if MRSA is still being spread among family members.

MRSA infections are relatively widespread and decolonization of MRSA carriers can prevent its transmission in the public.

References

1. Yiek et al. Success rates of MRSA decolonization and factors associated with failure    Antimicrobial Resistance & Infection Control 2022; 11:143.

2. Lee AMM, Francois P, Renzi G, Schrenzel J, Vernaz N, Pittet D, Harbarth S. Impact of combined low‑level mupirocin and genotypic chlorhexidine resistance on persistent methicillin‑resistant staphylococcus aureus carriage after decolonization therapy: a case‑control study. Clin Infect Dis Off Publ Infect Dis Soc Am; 2011. 52.

3. Sai et al. Efficacy of the decolonization of methicillin resistant Staphylococcus aureus carriers in clinical practice. Antimicrobial Resistance and Infection Control 2015; 4:56.

4. Gemmel CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE, et al.

5. Guidelines for prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother.2006;57:589–608.

6. Calfee DP, Salgado CD, Milstone AM, et al. Strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014; 35: 772-96.

7. Climo MW, Sepkowitz KA, Zuccotti G, et al. The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasiexperimental multicenter trial. Crit Care Med. 2009; 37: 1858–1865.